Our mission is to provide comprehensive personalized molecular solutions to inform cancer care.
NantOmics, a member of the NantWorks ecosystem of companies, is a leader in molecular diagnostic testing and the first company to employ an integrated panomic approach to inform personalized treatment options for patients with cancer. Combining DNA sequencing, RNA sequencing, and quantitative proteomics, NantOmics offers extensive testing capabilities that provide a comprehensive molecular profile of a patient’s cancer. Our proprietary analytical platform delivers molecular diagnostic capabilities that provide actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care.
For inquiries contact 1.301.977.3654.
Patrick Soon-Shiong, MD, FRCS (C), FACS - CEO & Founder
Dr. Patrick Soon-Shiong is a physician, surgeon, and scientist who has pioneered novel therapies for both diabetes and cancer, published more than 100 scientific papers, and has more than 95 issued patents on groundbreaking advancements spanning a myriad of scientific and medical fields.
Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig-to-man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA-approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. (In 2014, phase 3 trials revealed a 48 percent pathological complete remission in triple negative breast cancer with Abraxane treatment prior to surgery.) Abraxane is now approved in many countries across the globe, and sales are expected to reach a billion dollars in 2016.
From 1997 to 2010, Dr. Soon-Shiong has served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners and Abraxis BioScience. In 2011 he founded NantWorks, an ecosystem of companies with a mission to create a transformative global health information and next-generation pharmaceutical development network for the secure sharing of genetic and medical information, empowering doctors to treat patients with proven precision at the point of care and ultimately improve the lives of individuals everywhere.
Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award.
Follow Dr. Soon-Shiong on Twitter @solvehealthcare.
Shahrooz Rabizadeh, PhD - Chief Scientific Officer
Shahrooz Rabizadeh, PhD is the Chief Scientific Officer at NantOmics, LLC and at NantBioScience, Inc. Shahrooz received his PhD degree in neuroscience at the University of California, Los Angeles and trained as a postdoctoral fellow in Molecular Biology at Massachusetts General Hospital and Genetics at Harvard Medical School. Previously, Shahrooz was the Director of Molecular Drug Discovery at Abraxis BioScience, Inc. and an Adjunct Assistant Professor of Bioengineering at the University of California, Los Angeles. Prior to Abraxis, he co-directed the Discovery Translation Unit at the Buck Institute, where he also served as an Assistant Research Professor.
Todd Hembrough, PhD - President of Proteomics
Todd Hembrough, PhD is the President of Proteomics at NantOmics where he oversees R&D, operations, and the clinical proteomics laboratory. Todd obtained his Ph.D. in Biochemistry from the University of Virginia, studying the role of proteinases in tumor growth and invasion. Prior to NantOmics, Todd was a leader of the translational oncology efforts at EntreMed, focusing on defining druggable molecular pathways and inventing new drugs to target these pathways. Todd later became the Chief Scientific Officer and Head of R&D at OncoPlex Diagnostics and Expression Pathology where he led the development and commercial launch of the first quantitative proteomic assays performed on formalin-fixed, paraffin-embedded tissue.
Steve Benz, PhD - President of Genomics
Steve is the President of Genomics at NantOmics and oversees the computational pipelines and reporting solutions for all genomic data. Steve obtained his PhD and MS in Biomolecular Engineering and Bioinformatics at the University of California, Santa Cruz. While at UC Santa Cruz, Steve co-developed the Cancer Genome Browser and the pathway analysis engine, Paradigm, which he and his colleagues at Five3 Genomics used to contribute to The Cancer Genome Atlas project. Prior to NantOmics, Steve was the Co-Founder and Chief Executive Officer of Five3 Genomics. Steve held a research position at the Buck Institute for Research in Aging in Novato, CA where he modernized the microarray analysis pipeline used by the Genomics Core.
Mark T. Johnson, PhD, MD, DABMG - Medical Director
Mark is the Medical Director of NantOmics where he oversees the clinical genome sequencing facility and clinical reporting. Mark received his M.D. and Ph.D. degrees at Case Western Reserve University. Through his Doctoral Dissertation project, he generated the first mouse models for several inborn errors of metabolism. Mark completed his residency in Pediatrics and Medical Genetics at University Hospitals of Cleveland, and then he joined the faculty of the Department of Genetics at Case Western where he established a research program in reproductive genetics. As a Research Assistant Professor at the University of Michigan, Mark initiated a pioneering project to study the effects of aneuploidies in early mouse embryos. Before joining NantOmics, Mark ran a start-up company that developed novel approaches for performing genetic analyses, particularly for samples that contain very small numbers of cells.
Robert Heaton, MD - Medical Director
Robert is the Medical Director for NantOmics in Rockville, Maryland where he oversees the clinical reporting for the quantitative proteomics results. Robert is board certified in anatomical and clinical pathology. He is a graduate of Georgetown Medical School and has over 25 years of practice experience. His professional pathology career began in the United States Navy and has continued with the Advanced Pathology Associates group in the Washington, DC area.